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List of abbreviations 
AEBSF 4-(2-aminoetil)-benzolsulfonil-fluorid 
ALK-1 activin receptor-like kinase 1 gene  
AP-1 activator protein-1 
APAH  associated pulmonary arterial hypertension 
APTT activated partial thromboplastin time 
APT acute pulmonary thromboembolism 
BCR-Abl break point cluster - Abelson tyrosine kinase 
BMPR2  bone morphogenetic protein receptor type2 
CaM calmodulin 
CI cardiac index 
CINC-1, CINC-2α/β  cytokine-induced neutrophil chemoattractant 
CNTF ciliary neurotrophic factor 
CO cardiac output 
CO2 carbon dioxide 
COPD chronic obstructive pulmonary disease 
cAMP cyclic adenosine monophosphate   
cGMP    cyclic guanosine monophosphate 
CTEPH chronic thromboembolic pulmonary hypertension 
ECL    enhanced chemiluminescence 
ECM     extracellular matrix 
EF    ejection fraction  
ERA    endothelin receptor antagonist  
ERK ½ extracellular signal-regulated kinase  
FDA  US Food and Drug Administration 
Fract fractalkine 
GM-CSF granulocyte-macrophage colony-stimulating factor  
GSK-3β  glycogen synthase kinase-3β 
HE    hematoxylin and eosin 
HIV     human immunodeficiency virus 
ICAM intracellular adhesion molecule 
IĸB inhibitor of kappa B 
IL-1α     interleukin-1α 
INF    interferon 
i.p.    intraperitoneal 
IP-10 interferon gamma-induced protein-10 
i.v. intravenous 
KH    chronic hypoxic 
LDL    low density lipoprotein  
LIX  lipopolysaccharide induced CXC chemokine 
LMWH low molecular weight heparin 
L-Sel L-selectin  
LV left ventricule    
MAPK    mitogen-activated protein kinase 
MCT     monocrotaline       
MIG  monokine induced by gamma interferon  
MIP-1α, MIP-3α   macrophage inflammatory protein 
MLCK    myosin light-chain kinase 
MMPs   matrix metalloproteinase      
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NO nitrogen monoxide 
Nrf-2 nuclear factor erythroid 2- related factor 2 
PA pulmonary artery    
PASMC  pulmonary arterial smooth muscle cell  
PAH  pulmonary arterial hypertension 
PAP  pulmonary arterial pressure 
PARP poly (ADP-ribose) polymerase  
PBS     phosphate buffered solution  
PDE-5    phosphodiesterase type 5 
PDGF platelet derived growth factor 
PE    pulmonary embolism 
PESI pulmonary embolism severity index 
PH     pulmonary hypertension 
PI-3K-Akt  phosphatidylinositide 3-kinase-Akt  
PKG protein kinase G 
p.o. per os 
PVRI pulmonary vascular resistance index 
PWP     pulmonary wedge pressure 
RANTES   regulated on activation normal T cell expressed and secreted 
rtPA    recombinant tissue plasminogen activator 
RV    right ventricule 
SDS     sodium-dodecyl-sulphate  
SEM    standard error of the mean 
SK    streptokinase     
SMC     smooth muscle cell 
STAT signal transducer and activator of transcription protein 
Thym Chem   thymus chemokine    
TIMP-1 tissue inhibitor of metalloproteinase  
TL thrombolysis      
TNF-α    tumor necrosis factor-α  
tPA     tissue plasminogen activator 
TPG transpulmonary pressure gradient (mean PAP – mean PWP) 
UFH unfractionated heparin 
UH-SK  ultra-high-dose streptokinase 
UK urokinase 
VEGF vascular endothelial growth factor 
VSMCs   vascular smooth muscle cells 
VTS    venous thromboembolic syndrome  
WHO    World Health Organization 
  
Introduction 
PH has been defined as an increase in mean pulmonary arterial pressure > 25 mmHg at rest as 
assessed by right heart catheterization. Pulmonary arterial hypertension is a rare, progressive 
and incurable condition that often progresses undetected until it reaches the most severe 
stages. Although it is a rear disease, the number of recognized cases seems to be increasing.  
 
PAH is a progressive disease, it is characterized by obstructive proliferative changes in the 
lung microcirculation so called vascular remodelling. Our knowledge regarding the multiple 
pathological processes leading to the evolution of microvascular injury is still limited. 
Multiple lines of evidence support that vasoconstriction as well as inflammatory processes 
precede the remodelling of the pulmonary arterioles. Endothelial dysfunction interfere at 
various levels of the microvascular injury that is characterized by medial hypertrophy, intimal 
proliferative changes, adventitial thickening with perivascular inflammatory infiltrates. These 
alterations as well as the increased level of reactive oxygen species account for decreased 
apoptosis and increased proliferative vascular remodelling has significant role in the 
pathogenesis and progression of PH.  
 
Several medications were approved in PAH that improve symptoms and slow down 
progression. However currently there is no effective cure for PAH.  
 
PD5 inhibitors inhibit the cleavage of cGMP and induces pulmonary vasodilation by 
extending the vasodilator effect of nitrogen monoxid. 
 
Monocrotaline (MCT) is a C11 toxic macrocyclic pyrrolizidine alkaloid derived from plant 
Crotalaria spectabilis’ seed. Due to the substance the enlargement of the Golgi apparatus in 
the endothelial cells and pneumocites develops, leading to megalocytosis. As the formation of 
protein structure is inhibited in this organelle lack of the membrane proteins occur resulting in 
compensatory proliferative and anti-apoptotic factor induction and the NO signal transduction 
pathway is impaired. 
 
 
 
 
Own experiments in rat PH model 
Aim 
In our current experiments we observed the pulmonary effects of sildenafil in MCT induced 
rat PH model. We wanted to explore new mechanisms, contributing the known positive 
vasodilative effect of sildenafil in PH.  
We examined the mechanisms by which sildenafil can contribute to the attenuation of MCT 
induced inflammatory processes.  
 
We aimed to reveal the changes of the cytokine network, for which we used a broad spectrum 
cytokine array analysing the expression of 29 cytokines.  
 
We studied the activation pathway of nuclear factor kappa-light-chain-enhancer of activated 
B-cells, mitogen-activated protein kinases (MAPK) and the phosphatidylinositol 3-kinase-Akt 
(PI-3k-Akt) pathway, thus revealing the gene expression related signaltransduction pathways. 
 
Morphological changes were detected by histological studies, while biochemical changes 
were examined by Western blot analysis and immnhistological studies in addition to cytokine 
array.  
 
Experimental protocol 
In our experiments we used male Wistar rats (250 – 300 g). All animals were housed one or 
two per cage, under optimal laboratory conditions (controlled temperature, humidity and 
12:12 h- light-dark cycles) with free access to water and standard rodent chow. The animals 
were randomly assigned into four groups. 
 Sham group (n= 6) receiving i.p. injection of isotonic saline (0.1 ml/kg) on day 0. 
 
 Sham+ sildenafil (SLD) group (n= 8) receiving i.p. injection of isotonic saline (0.1 
ml/kg) on day 0 and sildenafil (2 mg/kg per day, per os, in the drinking water) from 
day 0 to day 28.  
 
 Pulmonary hypertension (PH) group (n= 8) receiving 60 mg/kg i.p. injection of MCT 
on day 0.  
 Pulmonary hypertensive + sildenafil (PH+SLD) group (n= 8) receiving 60 mg/kg i.p. 
injection of MCT on day 0 and sildenafil (2 mg/kg per day, per os, in the drinking 
water) from day 0 to day 28. 
 
After 4 weeks animals were sacrificed by overdosing isoflurane and organs were removed and 
their weight was measured. Samples for molecular biological testing were frozen in liquid 
nitrogen and were stored at -80 °C. 
 
Survival studies were performed by using 10-10 animals. 
 
Lung histology and morphometric analysis 
Lungs were fixed in 6% formalin, embedded into paraffin and 5 µm thin sections were cut 
with microtome (Leica 2135). Sections were stained with haematoxylin–eosin and digital 
photos were taken (Olympus E-450 Digital SLR) at 200-fold-magnification. Average wall 
thickness of alveolar sac was determined at randomly chosen 50 different sites per section. 
Macrophages were counted in 5 non-overlapping high power fields in each sections. 
 
Inflammatory cytokine and adhesion molecules measurements using rat cytokine array 
kit 
The cytokine array assay was performed on lung homogenates, using rat cytokine array kit 
(R&D Systems; Biomedica Hungaria, Hungary). The list of measured cytokines are shown in 
Table 1. These arrays are based on binding between sample proteins and carefully selected 
capture antibodies spotted on nitrocellulose membranes. We examined tissue samples from all 
the 4 groups: Sham, Sham+ SLD, PH and PH+SLD groups. The array was performed as 
described by the manufacturer. Developed films were scanned and analysed by densitometry. 
The pixel volumes of the bands were determined using the NIH ImageJ 1.40 software. 
 
Immunohistochemical staining 
Histological sections were prepared followed by incubation with rabbit clonal antibodies 
(anti-CD34 - cat# 10097.10, clone: Q19-E, antibody 1:200 dilution and anti-NF-κB antibodies 
- Abcam, cat#ab86299 in 1:20 dilution) as primary antibodies. Following incubation with the 
primary antibodies sections were incubated with the secondary anti-rabbit antibodies 
(HISTOLS –R Detection System, anti-rabbit, Histopathology Ltd.) at room temperature than 
washed and cleared in xylene followed by fixation process.  
 
Immunoblotting / Western blot analysis 
Lung tissue samples (50 mg each) were homogenized, proteins were precipitated by 
trichloroacetate. Prepared samples were separated on 10% sodium-dodecyl-sulphate (SDS)–
polyacrylamide gels, and transferred to Protran nitrocellulose membranes. After blocking 
membranes were probed overnight at 4 oC with antibodies recognizing the following antigens: 
total-p38MAPK, phosphop38 MAPK (Thr180/Tyr182), phospho-extracellular signal-
regulated kinase (ERK)1/2 (Thr202/Tyr204), total ERK1/2, total GSK-3b, phospho-GSK-3b 
(Ser9), phospho-Akt (S473), total Akt, total-NF-κB, phospho-NF-κB (Ser536) (each 1:500 
dilution, Cell Signaling Technology). After incubation the nitrocellulose membranes were 
incubated with goat anti-rabbit horseradish peroxidase conjugated secondary antibody (1:3000 
dilution; Bio-Rad) at room temperature. The antigen-antibody complexes were visualized 
with enhanced chemiluminescence (ECL) labelling using an ECL immunoblotting detection 
system (Amersham Biosciences). Developed films were scanned and the pixel volumes of the 
bands were determined using the NIH ImageJ 1.40 software. 
 
Data analysis 
Data were analysed using the Kolmogorov-Smirnov normality test followed by the one-way 
Anova test and Bonferroni post hoc multiple comparison test. Differences were considered 
significant at p < 0.05. Analyses were performed using IBM SPSS Statistics 20. 
 
Results 
Effects of sildenafil treatment on histological changes of the lung 
The mean wall thickness of alveolar sac was 3.31 ± 0.88 mm. CD-34 immunohistochemistry 
that indicates vascularization and vascular remodelling showed sporadic weak positivity. 
Sildenafil treatment alone did not cause any change neither in the wall thickness of alveolar 
sac nor in macrophage infiltration. In MCT treated animals, increased vascular wall thickness 
and due to inflammatory cell recruitment, the appearance of these cells and increased alveolar 
wall thickness have been detected in pulmonary hypertensive rats. The mean wall thickness of 
alveolar sac increased to 9.77 ± 2.63 mm vs 3.31 ± 0.88 µm (p < 0.05). As a result of MCT 
treatment a markedly increased macrophage count and macrophage infiltration have also been 
revealed. We could also detect extensive vascular remodelling in the small pulmonary vessels. 
In the sildenafil treated group we detected a markedly reduced alveolar sac wall thickness 
compared to the MCT treated animals (alveolar sac wall thickness 8.1 ± 1.47 µm vs 9.77 ± 
2.63 µm (p < 0.05)) facilitating gas diffusion.  Furthermore as a result of sildenafil treatment 
the lumen of affected vessels reopen resulting in reduced vascular resistance and pulmonary 
arterial blood pressure.  
All these findings from the very beginning supported our hypothesis according to which 
sildenafil has beneficial effects in pulmonary hypertension and that is not just the well-known 
vasodilator effect, but also the result of anti-inflammatory effect. 
 
Effects of sildenafil treatment on cytokine expressions 
MCT significantly increased the expression of several cytokines and chemoattractant proteins 
including IL-1α, CINC-1, CINC-2, LIX, MIG, MIP-1α and MIP-3α. Sildenafil treatment 
attenuated the activation of these cytokines. The changes of these cytokines for MCT and 
sildenafil treatment is shown in Figure 1 and Table 1. 
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Figure 1: Rat cytokine array kit.  
Different spots represent the cytokines and chemokines respectively.  
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Table 1:  Rat cytokine array kit 
The bold marked cytokines showed the most significant changes where the density of the spots of 
the PH group increased compared to the sham group, and the density of the PH + SLD group 
reduced compared to the PH group. In the case of the italic marked cytokines the density of the 
spots was higher in the sham group than in the PH group. The non-marked cytokines did not show 
any changes.  
 
Effects of sildenafil treatment on NF-κB activation 
Expression of most the aforementioned cytokines that were significantly induced by MCT 
treatment are regulated by NF-κB transcription factor. In our studies we determined NF-κB 
activation by immunoblotting and immunohistochemistry utilizing phospho- NF-κB p65 
specific primary antibody among the various groups. Phospho-NF-κB p65 
immunohistochemistry showed sporadic patchy weak background positivity in the Sham 
group. A very few of the nuclei demonstrated strong positive staining indicating nuclear 
translocation of NF-κB. NF-κB activation and nuclear translocation was basically identical to 
control among the sildenafil treated animals (without MCT treatment). On the other hand 
MCT treatment caused a massive activation and nuclear translocation of NF-κB in the 
endothelial and epithelial cells of the lung tissues in the pulmonary hypertensive rats. The 
phosphorylation thereby activation of NF-κB significantly reduced by sildenafil treatment in 
MCT induced pulmonary hypertensive animals, as inhibits detaching of IĸB from the NF-κB 
molecule leading to the inhibition of NF-κB translocation to the nucleolus and the complex 
remains in the cytoplasm. The translation of mRNS of different proinflammatory proteins, 
growth factors and apoptosis regulating proteins is pNF-κB dependant gene expression 
process and due to lack of a very important regulating molecule it cannot happen.  
 
Effect of sildenafil on PI-3K-Akt and MAPK signalling pathway  
NF-κB activation is regulated by various kinase signalling pathways including PI-3K-Akt and 
MAPK pathways. Therefore, we assessed the activation of these pathways by immunoblotting 
utilizing phosphorylation-specific primary antibodies. The phosphorylation thereby activation 
of Akt was not detectable in control lung tissues. Sildenafil alone slightly increased Akt 
activation, although, it did not reach the level of statistical significance. MCT treatment 
significantly increased Akt phosphorylation that was further enhanced by sildenafil 
administration.  
The phosphorylation of Akt’s downstream target GSK-3b showed similar patter among the 
different groups as that of Akt verifying Akt activation.  
Since cGMP was reported to regulate ERK1/2 and p38 among the MAPKs, we studied the 
effect of MCT and sildenafil on them. In the control lungs with or without sildenafil 
treatment, a slight phosphorylation of ERK1/2 (pERK 1 and 2) was observed. In MCT treated 
lungs a moderate activation of ERK1/2 occurred that was slightly decreased by sildenafil 
treatment, however, none of these changes reached the level of statistical significance. The 
p38 MAPK activation/phosphorylation in control lungs was undetectable that was slightly 
elevated by sildenafil treatment. MCT induced a robust activation of MAPK signalling 
pathway. The increased level of the phosphorylated form of p38MAPK the pp38MAPK was 
observed due to oxidative stress in pulmonary hypertension that was significantly diminished 
by sildenafil as in case of cytokines and chemokines. Because the inhibition of IĸB function is 
not supressed by the MAPK, the IĸB remains in complex with NF-ĸB which remains under 
inhibition, thereby promoting cell survival. 
 
Conclusion 
Sildenafil has a strong cytoprotective effect; however, it causes vasodilation, thereby 
optimizing the pulmonary circulation, oxygenation, strongly inhibits apoptosis and 
proinflammatory biochemical pathways and suppresses these signalling mediators. In 
summary: in the future sildenafil can receive a greater role in the therapy of inflammatory 
diseases. 
 
Acute pulmonary embolism (PE) 
Acute pulmonary embolism is a relatively common condition that may become critical and 
associated with increased mortality. 
 
 
 
Pulmonary hypertension in acute pulmonary embolism 
Embolic masses lead to mechanical obstruction of pulmonary arteries resulting in increased 
pressure in pulmonary arteries. Nevertheless it is not just the mechanical obstruction which 
leads to pulmonary hypertension in PE. Due to in situ thrombosis the coagulation cascade, 
platelets and endothelial cells are activated resulting in endothelial dysfunction. Certain 
factors such as shear stress, increased pressure, inflammation, certain cytokines, extracellular 
matrix remodelling, endogenous vascular elastase, plasminogen activator/plasmin system and 
matrix metalloproteases are also involved in the pathogenesis.  
Oxidative stress and leucocyte activation also play role but we have only limited data 
regarding the pathology of oxidative stress associated with acute pulmonary embolism from 
human studies. 
Further biochemical substances such as matrix metalloproteases (MMPs) are also involved in 
acute right ventricular failure associated with acute massive pulmonary embolism. Activated 
neutrophils release increased amounts of reactive oxygen species including superoxide, thus 
activating MMPs. Particularly important for the pulmonary vasculature, increased mechanical 
stretch of the vessel wall promotes the formation of reactive oxide species, thus further 
contributing to enhanced MMP release. Moreover, activated MMPs (particularly MMP-2 and 
–9) disrupts vascular structure by causing fragmentation of internal elastic laminae, which is 
an early histopathologic feature of pulmonary hypertension. Another factor mechanism that 
may play a role in acute pulmonary embolism-induced pulmonary hypertension is the possible 
involvement of MMPs in the modulation of vascular tone. Activated MMPs may induce the 
degradation of bigendothelin-1 into endothelin 1-32, which has potent vasoconstrictor effects. 
It is known that fibrinolytic drugs such as tissue plasminogen activator (rt-PA; alteplase), 
which are used to induce clot lysis, may promote MMP-9 release by neutrophils. Some 
members of our study group were first to show increased MMP-9 levels following fibrinolysis 
with alteplase or streptokinase in patients with massive and submassive pulmonary embolism, 
and this effect was associated with no significant changes in plasma TIMP-1 levels. These 
findings suggest that thrombolytic therapy increases net MMP activity, and this alteration may 
increase the risk of intracerebral haemorrhage, which is the most feared bleeding complication 
of thrombolysis, especially because it is fatal in more than 50% of cases. Although it not 
known whether increased MMP-9 levels after the use of thrombolytic agents explains 
intracerebral haemorrhage following fibrinolysis for acute pulmonary embolism, it is possible 
that the MMP inhibitors may decrease the risk of intracerebral haemorrhage or other bleeding 
complication after thrombolysis for this condition, as previously shown in rodents. 
Imbalance between vasoactive substances may also play role in the development of acute 
pulmonary hypertension associated with acute pulmonary embolism. More recently, 
significant haemolysis has been shown in animal models of APT, and increased arginase I and 
II activity has been implicated in the increased pulmonary vascular resistance commonly 
found after APT. The authors showed that haemolysis-induced increases in arginase I could 
deplete l-arginine, therefore impairing endogenous NO formation. Under normal conditions, 
haemoglobin is confined to red blood cells, and therefore NO produced by endothelial cells 
reach smooth muscle cells producing vasodilation. Impaired NO availability resulting from 
increased cell-free haemoglobin concentrations has been shown as a novel important 
mechanism of human disease involving haemolysis-induced vasoconstriction and endothelial 
dysfunction resulting of NO scavenging by haemoglobin  
Our hypothesis was that lung embolization and thrombolysis increases cell-free haemoglobin 
concentrations that impair NO bioavailability as a direct result of NO scavenging 
(consumption), as previously shown in other disease conditions associated with haemoglobin 
decompartmentalization into plasma Our study incorporated both experimental lung 
embolization model and clinical study. 
 
Own experiments on animal pulmonary embolism model and in clinical 
practice 
Aim of the study 
Our hypothesis was that lung embolization and thrombolysis increases cell-free haemoglobin 
concentrations and NO consumption by plasma resulting in reduced NO bioavailability 
leading to increased vascular resistance. 
In the present study, we examined whether experimental lung embolization with autologous 
blood clots or with the infusion of microspheres increase cell-free haemoglobin levels and NO 
consumption by plasma. 
To validate our experimental findings, we compared free haemoglobin concentrations and NO 
consumption by plasma samples from patients with APT with those from healthy controls.  
In clinical study we examined the effects of thrombolysis on cell-free haemoglobin levels and 
NO consumption. 
 
Materials and methods 
Animal model 
Measurements were done at Faculty of Medicine of Ribeirão Preto, University of São Paulo, 
Brasil. Experiments fit in with guidelines of the Faculty of Medicine of Ribeirão Preto, 
University of São Paulo, and the animals were handled according to the guiding principles 
published by the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Fourteen male lambs weighing 17.2 ± 2.0 kg (mean ± SD) were used in this study. 
The animals were anesthetized with intramuscular ketamine and xylazine (10–15 mg/kg and 
0.1–0.2 mg/kg, respectively), relaxed with pancuronium (0.1 mg/kg bolus and 0.5–1 mg/hr; 
IV), tracheally intubated, and their lungs were artificially ventilated with room air using 
volume control mechanical ventilation.  The tidal volume was set at 15 mL/kg, and the 
respiratory rate was adjusted to maintain a baseline physiologic arterial carbon dioxide 
tension. Anaesthesia was maintained with intramuscular injections of ketamine (5 mg/kg) and 
midazolam (0.5 mg/kg) every 30 minutes. Fluid-filled catheters were placed into the left 
femoral artery and right femoral vein for mean systemic arterial pressure monitoring via a 
pressure transducer and fluid administration, respectively. A 7.5F balloon-tipped Swan-Ganz 
thermodilution catheter was placed into the pulmonary artery via the left femoral vein. Its 
correct location being confirmed by detection of the typical pressure wave of this artery. The 
catheter was connected to pressure transducers to allow the monitoring of mean pulmonary 
artery pressure, central venous pressure, and pulmonary artery occlusion pressure. The 
transducers were zeroed at the level of the right heart and recalibrated before each set of 
measurements. Thermodilution cardiac output measurements were determined in triplicate by 
injecting 3 mL of saline and the results recorded (DX2010 Monitor, Dixtal do Brasil, Manaus, 
Brasil). The heart rate was measured using a surface electrocardiogram (lead I). The cardiac 
index, systemic vascular resistance index, and pulmonary vascular resistance index (PVRI) 
were calculated by standard formulae using the thermodilution curves and the results of 
invasive pressure measurements.  
The animals were randomly assigned to one of three experimental groups: 
1. Sham group (n = 4), in which non-embolized animals received only saline infusions. 
2. Acute pulmonary embolism (APT) group (n = 5), in which APT was induced by infusing 
autologous blood clots for 5 to 10 minutes via a large-bore cannula placed in the right 
atrium. The clots derived from venous blood samples (5 ml/kg) collected and allowed to 
clot for at least 60 minutes, and then cut into 2- to 3-mm cubes. 
3. Embolism with microspheres (EMB) group (n = 5), in which the animals received 
repeated intravenous injections (every 30 s) of 300 μm microspheres (Sephadex G50; 
Pharmacia Fine Chemicals; Uppsala, Sweden) into the inferior vena cava over 5 to 10 
minutes. The amount of microspheres infused in each male lamb was adjusted to induce 
an increase of 20 mm Hg in mean pulmonary artery pressure.  
Hemodynamic evaluation was performed 30 and 180 minutes after lung embolization. 
Arterial blood samples were drawn at BL, and 30 and 180 minutes after lung embolization for 
plasma-free haemoglobin and plasma NO consumption measurements. 
 
Clinical study 
This study was carried out in accordance with the ethical guidelines of the 1975 Declaration 
of Helsinki and the permission of the Institutional Scientific and Human Research Ethics 
Committee of the University of Pécs (810/2001). Each patient provided written informed 
consent and was informed clearly about the details of study and blood sampling. 
We prospectively screened patients with high and intermediate risk of pulmonary embolism, 
according to the latest European Society of Cardiology guidelines. A group of 28 healthy 
control subjects were randomly selected from the local population. About 14 Caucasian 
patients were divided into two therapeutic groups using block randomization: 7 patients 
received ultra-high-dose (9 million units/6 hours) streptokinase (UH-SK), according to 
previous studies and to our hospital experience, and 7 patients received alteplase (tPA) 100 
mg/2 hours to induce thrombolysis.  
 
The inclusion criteria were: 
 Extension of the unperfused lung area >50%, which were verified with spiral CT and/or 
perfusion lung scan  
with  
 hemodynamic instability (systolic blood pressure < 90 mm Hg)  
or  
 with stable haemodynamic with echocardiographic findings such as D-sign, increased 
right ventricular pressure (>40 mm Hg), and elevated troponin I levels (>0.11 ng/l).  
Exclusion criteria: 
 Patients who declined to give consent 
or 
 advanced malignant disease 
or  
 absolute contraindication to thrombolysis. 
 
A single 5000 IU intravenous bolus of unfractionated heparin (UFH) was administered to 
patients with suspected APT if the patient had not already received low–molecular weight 
heparin previously. The patients received immediate oxygen therapy at 50% or 100% with a 
face mask. Morphine was given as IV bolus of 2 mg for pain relief. Patients with circulatory 
shock received inotropic support according to their requirement to keep the mean arterial 
pressure at 70–80 mm Hg. Norepinephrine was used at 5–20 μg/min, whereas dobutamine was 
used at 5–10 μg/kg/min. Dobutamine was added to norepinephrine when norepinephrine had 
to be used greater than 10 μg/min. None of the patients required mechanical ventilation. 
Patients with suspected hypovolemia received 20 ml/kg/30 min crystalloids. Maintenance 
crystalloid infusion was 1.5– 2 ml/kg/hr. Further supportive treatment was homogenous: 
pantoprazole 40 mg IV twice a day, and noradrenaline and/or dobutamine were given as 
positive inotropic drugs if required. In patients treated with streptokinase, UFH infusion was 
continued according to heparin adjustment nomogram only after thrombolysis, whereas 
continuous UFH infusion was given simultaneously with alteplase. UFH was continued in the 
first 48 hours, or therapeutic dose of low–molecular weight heparin was commenced. The 
effectiveness of thrombolytic treatment was controlled by a second-look spiral CT or 
perfusion lung scan. If any of the examinations did not verify at least 30% decrease in the size 
of unperfused lung area after the first treatment cycle, thrombolysis was repeated after 24 
hours. If the fibrinogen level had been lower than 2 g/l before the second thrombolytic cycle, 
fresh frozen plasma was administered. Arterial blood samples were collected before 
thrombolysis as a BL value and then at 8 hours, 1, 3, 5, and 30 days after thrombolysis to 
measure plasma-free haemoglobin concentrations and NO consumption by plasma. 
Samples from healthy subjects (n = 28) were collected to compare plasma-free haemoglobin 
concentrations and NO consumption by plasma from APT patients with those found in healthy 
subjects. 
Measurement of haemoglobin concentrations 
The plasma-free haemoglobin concentrations measured with a commercially available 
haemoglobin detection kit (Cat.#K013H1, Arbor Assays, Ann Arbor, MI) according to 
manufacturer’s instructions. 
NO consumption assay 
We used a previously described (14, 24) NO consumption assay to assess NO consumption by 
plasma samples. Briefly, a solution of 40 μM DETA NONOate (Cayman Chemical, Ann 
Arbor, MI) in phosphate-buffered saline (pH 7.4) was prepared in a glass vessel purged with 
nitrogen inline with an NO chemiluminescence analyser (Sievers Model 280 NO Analyser, 
Boulder, CO) to produce a steady-state NO signal of about 40–60 mV. This signal is 
generated by the decay of DETA NONOate and the release of NO from DETA NONOate, 
thus producing a stable Bl signal. Thereafter, we injected 50 μl of plasma samples in triplicate, 
which produced decreases in Bl NO signal (NO consumption, mV). Data were analysed using 
the software program ORIGIN Version 6.1 (Originlab, Northampton, MA), and the area under 
the curve of decreasing NO signal over time was measured for each plasma sample.  
 
Statistical Analysis 
Two-way (embolization vs. time) analysis of variance (ANOVA) and one-way ANOVA for 
repeated measures followed by Bonferroni post-tests were used to compare hemodynamic or 
biochemical parameters. The Spearman correlation (rs, p) was calculated for associations 
between plasma-free haemoglobin concentrations and NO consumption or other 
hemodynamic parameters. Plasma-free haemoglobin concentrations and NO consumption by 
clinical samples were compared by the Student t-test, and the changes induced by 
thrombolysis in these parameters were evaluated by one-way ANOVA for repeated measures 
and Bonferroni post-test. The data are shown as mean ± SEM, and a p value  
 
RESULTS 
Experimental embolism studies 
In order to examine whether experimental pulmonary embolism increases NO consumption by 
plasma secondarily to increased plasma levels of free haemoglobin, we carried out 
measurements in plasma samples from embolized animals. We tested this hypothesis in two 
different animal models of pulmonary embolism (thromboembolism and microsphere 
embolism) because thromboembolism could promote increases in plasma-free haemoglobin 
concentrations different from those found in microsphere embolism. 
As expected, lung embolization increased both PVRI and mean pulmonary arterial pressure in 
both animal models (p < 0.05), and these hemodynamic alterations were associated with 
increased plasma heme concentrations (p < 0.05) and NO consumption by plasma samples (p 
< 0.05). We found significant correlation between NO consumption by plasma samples and 
heme concentrations (p < 0.001). In parallel with these results, we found significant 
correlations between PVRI (p < 0.001) or MPAP (p < 0.001) and NO consumption by plasma 
samples. 
 
Clinical findings 
In order to validate our experimental results, we examined whether clinical acute pulmonary 
embolism increases NO consumption by plasma in association with increased plasma levels of 
free haemoglobin. Therefore, we measured these parameters in plasma samples from patients 
with APT. In agreement with our experimental results, we found higher plasma heme 
concentrations and NO consumption by plasma samples from patients with APT (both p < 
0.05) compared with healthy subjects. Moreover, both parameters increased immediately after 
thrombolysis with alteplase or streptokinase (both p < 0.05). Interestingly, these alterations 
apparently peaked earlier in patients treated with streptokinase (at day 1 after thrombolysis), 
as compared with patients treated with alteplase (at day 3 after thrombolysis). Again, we 
found significant correlation between NO consumption by plasma samples and heme 
concentrations (p < 0.001). 
 
Conclusion 
Our findings support the suggestion that the physiological control of vascular function may be 
impaired during acute PE. Our study was the first to show that both experimental and clinical 
PE increases NO consumption by plasma in association with increased haemolysis. However, 
our present results expand those previous findings that impaired endogenous NO formation is 
a mechanism exerting a very relevant protective role in the cardiovascular responses to acute 
PE and show that haemoglobin decompartmentalization during acute PE consistently 
increases NO consumption by plasma and may result in lower vascular NO bioavailability. 
Our results revealed a new mechanism involving increased haemoglobin 
decompartmentalization and augmented NO consumption, possibly contributing to the 
hemodynamic derangement of acute PE. Moreover, we showed for the first time that 
thrombolytic therapy transiently further aggravates this alteration in patients with acute PE. 
Our findings may have several clinical implications and help to understand complex 
mechanisms that play role in the hemodynamic changes and pulmonary hypertension 
associated with acute PE. 
